Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q4 2024 (December 31)4holders
0new positions
0sold out
$9.66avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Hantz Financial Services, Inc. ($1.5M), Rhumbline Advisers ($347K) and GAMMA Investing LLC ($67K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 777 shares bought and 7,809 shares sold, net −7,032 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Hantz Financial Services, Inc. | 0.03% | Reduce -4.2% | 157,046 | $1.5M |
| Rhumbline Advisers | 0.00% | Reduce -2.4% | 35,945 | $347K |
| GAMMA Investing LLC | 0.01% | Add +12.6% | 6,956 | $67K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 40 | $386 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.